Crohn’s Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements by DelveInsight | AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Crohn’s Disease pipeline constitutes 70+ key companies continuously working towards developing 80+ Crohn’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Crohn’s Disease Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn’s Disease Market.

 

Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).

 

Some of the key takeaways from the Crohn’s Disease Pipeline Report: 

Companies across the globe are diligently working toward developing novel Crohn’s Disease treatment therapies with a considerable amount of success over the years. 

Crohn’s Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn’s Disease treatment 

Emerging Crohn’s Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn’s Disease market in the coming years. 

In May 2024, In Eli Lilly and Company’s (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderate to severe Crohn’s disease, regardless of prior biologic treatment failure, experienced statistically significant and clinically meaningful improvements in various clinical and endoscopic measures after one year of treatment with mirikizumab compared to placebo.

In March 2024, Developed by Janssen Biotech, Stelara is a biologic therapy used to treat various conditions, such as moderate to severely active Crohn’s disease, active ulcerative colitis (UC), active psoriatic arthritis, and plaque psoriasis. It can be administered either subcutaneously or intravenously. The subcutaneous injection comes in two formulations: 45mg/0.5ml and 90mg/ml, both available in single-dose prefilled syringes.

In May 2023, For those with moderate to severe active Crohn’s disease who did not respond well to or were intolerant of one or more tumour necrosis factor blockers, the FDA has approved Rinvoq (upadacitinib). The first oral medicine for the management of Crohn’s disease that has received FDA approval is called Rinvoq.

 

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).

 

Get a Free Sample PDF Report to know more about Crohn’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight

 

Emerging Crohn’s Disease Drugs Under Different Phases of Clinical Development Include:

MORF 057: Morphic Therapeutic

OTL-104: Orchard Therapeutics

TP-317: Thetis Pharmaceuticals

AZD 7798: AstraZeneca

IMU 856: Immunic

CBP-307: Suzhou Connect Biopharmaceuticals

PF-06651600: Pfizer

Deucravacitinib: Bristol-Myers Squibb

E6011: Eisai Inc

Guselkumab: Janssen Pharmaceutical

Mirikizumab: Eli Lilly and Company

Filgotinib: Gilead Sciences

RHB-104: RedHill Biopharma

Ozanimod: Celgene Corporation

Brazikumab: AstraZeneca

 

Crohn’s Disease Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

Oral

Parenteral

Intravenous

Subcutaneous

Topical

 

Crohn’s Disease Molecule Type

Crohn’s Disease Products have been categorized under various Molecule types, such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

 

Crohn’s Disease Pipeline Therapeutics Assessment

Crohn’s Disease Assessment by Product Type

Crohn’s Disease By Stage and Product Type

Crohn’s Disease Assessment by Route of Administration

Crohn’s Disease By Stage and Route of Administration

Crohn’s Disease Assessment by Molecule Type

Crohn’s Disease by Stage and Molecule Type

 

DelveInsight’s Crohn’s Disease Report covers around 80 + products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

 

Further Crohn’s Disease product details are provided in the report. Download the Crohn’s Disease pipeline report to learn more about the emerging Crohn’s Disease therapies

 

Some of the key companies in the Crohn’s Disease Therapeutics Market include:

Key companies developing therapies for Crohn’s Disease are – Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others.

 

Crohn’s Disease Pipeline Analysis:

The Crohn’s Disease pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.

Crohn’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Crohn’s Disease drugs and therapies

 

Crohn’s Disease Pipeline Market Drivers

High prevalence of Crohn’s Disease, increase in Drug Development for Crohn’s treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn’s Disease Market.

 

Crohn’s Disease Pipeline Market Barriers

However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn’s Disease Market growth.

 

Scope of Crohn’s Disease Pipeline Drug Insight    

Coverage: Global

Key Crohn’s Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others

Key Crohn’s Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others

Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies

Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers 

 

Request for Sample PDF Report for Crohn’s Disease Pipeline Assessment and clinical trials

 

Table of Contents 

1. Crohn’s Disease Report Introduction

2. Crohn’s Disease Executive Summary

3. Crohn’s Disease Overview

4. Crohn’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Crohn’s Disease Pipeline Therapeutics

6. Crohn’s Disease Late Stage Products (Phase II/III)

7. Crohn’s Disease Mid Stage Products (Phase II)

8. Crohn’s Disease Early Stage Products (Phase I)

9. Crohn’s Disease Preclinical Stage Products

10. Crohn’s Disease Therapeutics Assessment

11. Crohn’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Crohn’s Disease Key Companies

14. Crohn’s Disease Key Products

15. Crohn’s Disease Unmet Needs

16 . Crohn’s Disease Market Drivers and Barriers

17. Crohn’s Disease Future Perspectives and Conclusion

18. Crohn’s Disease Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×